Regulation of Self-Care Products in Canada

https://policybase.cma.ca/link/policy13802

POLICY TYPE  Response to consultation
DATE  2016-10-31
TOPICS  Pharmaceuticals, prescribing, cannabis, drugs
        Health care and patient safety

Documents

CMA Response: Regulation of Self-Care Products in Canada
Statement to the House of Commons Committee on Health addressing the opioid crisis in Canada
https://policybase.cma.ca/link/policy13936

POLICY TYPE
Parliamentary submission

DATE
2016-10-18

TOPICS
Pharmaceuticals, prescribing, cannabis, drugs
Population health, health equity, public health
Health care and patient safety

Documents

Opening Statement

House of Commons
Standing Committee on Health

Dr. Jeff Blackmer
Vice-President, Medical Professionalism
Canadian Medical Association
Ottawa
October 18, 2016

Check against delivery
Legalization, regulation and restriction of access to marijuana

https://policybase.cma.ca/link/policy11954

POLICY TYPE  Response to consultation

DATE  2016-08-29

TOPICS  Pharmaceuticals, prescribing, cannabis, drugs

Documents

CMA Submission
Legalization, Regulation and Restriction of Access to Marijuana

Government of Canada – Task Force on Marijuana
Legalization and Regulation

August 29, 2016

STATEMENT  |  DÉCLARATION

Choi statement - application d’horaire

Preamble – September 4, 2016: The CMA’s submission to the Task Force on Marijuana, Legalization and Regulation expresses the CMA’s interest in the health and welfare of Canadians who may use marijuana to treat health conditions. The CMA recognizes the need for a regulatory framework to ensure that the health and welfare of such individuals is protected.

The Task Force’s regulatory program, which is in the public interest, is sound, but it does not address issues that have been raised by CMA. It is important that these issues be addressed, particularly in terms of:

- Evidence-based public health policies
- Ensuring the safety and efficacy of cannabis
- Ensuring that the provisions of this Act are consistent with the public health objectives of the Act

As a result, the CMA’s submission offers the following recommendations for the provision of a framework for the control of marijuana (the Act) and the creation of the Cannabis Regulation and Control Board.

- Promoting public health and safety: It is important that the Act be consistent with the public health objectives of the Act.
- Ensuring safety and efficacy: It is important that the provisions of this Act be consistent with the public health objectives of the Act.
- Ensuring that the provisions of this Act are consistent with the public health objectives of the Act

The Task Force recommends that the provision of a framework for the control of marijuana be consistent with the public health objectives of the Act.

For reference: [CMA submission to the Task Force on Marijuana, Legalization and Regulation - p. 3 of 4]

http://policybase.cma.ca/link/policy11954

CMAPolicybase - Canadian Medical Association  p. 3
Health Canada’s Consultation on “Plain and Standardized Packaging”
https://policybase.cma.ca/link/policy13817

POLICY TYPE
Response to consultation

DATE
2016-08-12

TOPICS
Health care and patient safety
Pharmaceuticals, prescribing, cannabis, drugs

Documents
Consultation on the prescription drug list: Naloxone
https://policybase.cma.ca/link/policy11847

POLICY TYPE: Response to consultation
DATE: 2016-03-19
TOPICS: Pharmaceuticals, prescribing, cannabis, drugs

Documents
Regulatory framework for the mandatory reporting of adverse drug reactions and medical device incidents by provincial and territorial healthcare institutions.

https://policybase.cma.ca/link/policy11814

POLICY TYPE Response to consultation
DATE 2016-01-20
TOPICS Pharmaceuticals, prescribing, cannabis, drugs
Health care and patient safety

Documents